379231-04-6

Basic information

• Product Name: Saracatinib
• Synonyms: 7-[2-[4-Methylpiperazin-1-yl]ethoxy]-5-[[tetrahydropyran-4-yl]oxy]-4-[[6-chloro-2,3-Methylenedioxyphenyl]aMino]quinazoline;(S)-2-(4-(4-chlorophenyl)-2,3,9-triMethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(4-hydroxyphenyl)acetaMide;N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methyl-1-piperazinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-4-quinazolinamine Saracatinib (AZD0530);Saracatinib N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methyl-1-piperazinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-4-quinazolinamine;Saracatinib, >=98%;Gemcabene Calcium;N-(5-Chlorobenzo[d][1,3]dioxol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-(tetrahydro-2H-pyr;saracatinib
• CAS NO: 379231-04-6
• Molecular Formula: C27H32ClN5O5
• Molecular Weight: 542.03
• EINECS: 1592732-453-0
• Product Categories: Inhibitors;APIs;Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Protein Kinase Inhibitors and Activators
• Mol File: 379231-04-6.mol
• Article Data: 0

Chemical Properties

• Boiling Point: 671.25 °C at 760 mmHg
• Flash Point: 359.759 °C
• Appearance: /
• Density: 1.348
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.641
• Storage Temp.: -20°C
• Solubility: Soluble in DMSO (50 mg/ml) and ethanol (54 mg/mL with warming)
• PKA: 7.55±0.10(Predicted)
• Stability: Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.
• CAS DataBase Reference: Saracatinib(CAS DataBase Reference)
• NIST Chemistry Reference: Saracatinib(379231-04-6)
• EPA Substance Registry System: Saracatinib(379231-04-6)

Safety Data

• Hazardous Substances Data: 379231-04-6(Hazardous Substances Data)

Usage

Description

Saracatinib, also known as a dual inhibitor of the tyrosine kinases c-Src and Abl, is an orally available compound that effectively inhibits various cellular processes such as motility, migration, adhesion, invasion, proliferation, differentiation, and survival. It is characterized by its white solid appearance and has shown potential in COVID-19-related research.

Uses

Used in Pharmaceutical Industry:
Saracatinib is used as an oral, selective dual inhibitor of Src and ABL kinase for its ability to block cell motility, migration, adhesion, invasion, proliferation, differentiation, and survival. It is particularly effective in reducing osteoclast bone resorption through its effects on c-Src and has demonstrated potential in blocking dengue virus RNA replication through its effect on Fyn kinase.
Additionally, Saracatinib is used in COVID-19-related research as a potential therapeutic agent, highlighting its versatility and importance in the pharmaceutical industry.

References

Hennequin et al. (2006), N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor; J. Med. Chem., 49 6465 Green et al. (2009), Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530; Oncol., 3 248 de Wispelaere et al. (2013), The small molecules AZD0530 and Dasatinib inhibit dengue virus RNA replication via Fyn kinase; Virol., 87 7367 Shin et al. (2018), Saracatinib Inhibits Middle East Respiratory Syndrome-Coronavirus Replication In Vitro; Viruses, 10 283 Tang et al. (2020), Fyn kinase inhibition reduces protein aggregation, increases synapse density and improves memory in transgenic mice and traumatic Tauopathy; Acta Neuropathol. Commun., 8 96 Kaufman et al. (2015), Fyn inhibition rescues established memory and synapse loss in Alzheimer mice; Neurol., 77 953

InChI:InChI=1/C27H32ClN5O5/c1-32-6-8-33(9-7-32)10-13-35-19-14-21-24(23(15-19)38-18-4-11-34-12-5-18)27(30-16-29-21)31-25-20(28)2-3-22-26(25)37-17-36-22/h2-3,14-16,18H,4-13,17H2,1H3,(H,29,30,31)